| The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. | |
| | |
MedLine Citation:
|
PMID: 20561344 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the impact of value-based benefit design (VBBD) on adherence to diabetes medications. METHODS: Health Alliance Medical Plans piloted VBBD for diabetes medications for a subgroup of 5400 enrollees in January 2007 while keeping drug benefits unchanged for the remaining plan enrollees. A difference in difference method (DID) was used to evaluate the effect of VBBD based on pharmacy claim data. Patients with unchanged benefits in the same plan were used as the control group. Adherence was measured by the proportion of days covered. Propensity score weighting was used to balance characteristics of the case group and the control group. RESULTS: There were 71 patients in the case group and 5037 patients in the control group. The patients in the two groups had comparable characteristics after propensity score weighting. After the implementation of VBBD, the average copayment per 30 days of supply for diabetes medications decreased from $15.3 to $10.1 for the case group and increased from $14.6 to $15.1 for the control group. The probability of being adherent increased from 75.3% to 82.6% for the case group and was roughly unchanged from 79.1% to 78.5% for the control group. Propensity score-weighted DID analysis showed that patients with copayment reduction had greater odds of being adherent: odds ratio=1.56, P=0.03, 95% confidence interval 1.04-2.34. CONCLUSION: A VBBD program that reduced the copayment for diabetes medications by 36.1% reduced the number of nonadherent patients by 30.0%. |
| | |
Authors:
|
Feng Zeng; Jae Jin An; Robert Scully; Christina Barrington; Bimal V Patel; Michael B Nichol |
Related Documents
:
|
10183124 - Marketing medical services to an aging america. 16254084 - Who i am, who we are, and why: links between emotions and causal attributions for self-... 10377704 - A medical readiness model of health assessment or well-being in first-increment air com... 11545624 - Analysis of urinary prostacyclin and thromboxane/prostacyclin ratio in patients with rh... 1829714 - The effect of local government outreach efforts on the recipiency of selected medicaid ... 10314624 - The pa's role in medical research: implications for pa education. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research Volume: 13 ISSN: 1524-4733 ISO Abbreviation: Value Health Publication Date: 2010 Sep-Oct |
Date Detail:
|
Created Date: 2010-11-08 Completed Date: 2011-01-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883818 Medline TA: Value Health Country: United States |
Other Details:
|
Languages: eng Pagination: 846-52 Citation Subset: IM |
Copyright Information:
|
© 2010, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). |
Affiliation:
|
MedImpact Healthcare Systems, Inc, San Diego, CA 92131, USA. fzeng@medimpact.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Comorbidity Cost Sharing* Diabetes Mellitus / drug therapy*, economics* Female Humans Hypoglycemic Agents / economics*, therapeutic use Insurance Claim Review Insurance, Pharmaceutical Services / economics*, standards Male Medication Adherence / statistics & numerical data* Middle Aged Propensity Score Risk Assessment |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cost-effectiveness of therapeutic hypothermia to treat neonatal encephalopathy.
Next Document: Pollinator specificity, floral odour chemistry and the phylogeny of Australian sexually deceptive Ch...